Vir Biotechnology Narrows Third-Quarter Net Loss to $96.3 Million

Vir Biotechnology narrowed its third-quarter net loss to $96.3 million as research spending fell, while its cash and investments are expected to fund operations into the second half of 2028. For the quarter ended Sept. 30, the company recorded a loss of $0.57 per share, basic and diluted, compared with $1.17 per share a year earlier. Net loss was $163.1 million in the same quarter of 2025. Research and development expenses declined to $80 million from $151.5 million. The decrease reflected a $75 million milestone expense in the year-earlier quarter and collaboration cost recoveries in the latest quarter.

Source: TokenPost